Skip to content
Screener

Olema Pharmaceuticals, Inc. OLMA Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
LON
LeonaBio, Inc.LONA
$71.59M+64.5%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$436.76M+79.8%
Opko Health logo
Opko HealthOPK
$1.83B-7.3%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$443.28M+8.9%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$1.03B-6.4%

Other financials

Income statement

See full
Operating income-$58.0M-66.3%
Net income-$53.1M-74.7%
EPS (diluted)-$0.52-44.4%

Balance sheet

See full
Cash & equivalents$52.5M+3.8%
Total debt$956.0K-16.7%
Total equity$480.5M+25.3%
Total assets$530.6M+29.5%

Cash flow

See full
Operating cash flow-$46.0M-4.6%
CapEx-
Free cash flow-$34.5M-27.8%

Valuation

See full
Market cap$1.03B+202%
Enterprise value$979.11M+238%

Returns & leverage

See full
Return on equity-42.9%+1.3pp
Debt / equity0.0×
Current ratio10.9×-4.3×

Where this comes from

Reported directly by Olema Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Olema Pharmaceuticals, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 7:10 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-218156
Line itemMarch 31, 2026December 31, 2025
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025.
Common stock, $0.0001 par value; 490,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 87,332,971 and 81,376,449 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively.88
Additional paid-in capital1,131,5761,075,487
Accumulated other comprehensive (loss) income(460)621
Accumulated deficit(650,646)(597,557)
Total stockholders’ equity480,478478,559
Total liabilities and stockholders’ equity$530,645$533,430

Item 1. Financial Statements.

FAQ

What is Olema Pharmaceuticals, Inc.'s total liabilities & equity?
Olema Pharmaceuticals, Inc. (OLMA) reported total liabilities & equity of $530.65M in Q1 2026.
How has Olema Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
Olema Pharmaceuticals, Inc.'s total liabilities & equity increased by 29.5% year-over-year, from $409.64M to $530.65M.
What is the long-term trend for Olema Pharmaceuticals, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Olema Pharmaceuticals, Inc.'s total liabilities & equity has grown at a 9.3% compound annual growth rate (CAGR), from $342.72M to $533.43M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Olema Pharmaceuticals, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude